Aggressive B-cell lymphomas (ABL) as group of B-cell malignancies are relevant across the world—both in the developing and the developed world. There are significant differences in the incidence/prevalence of ABLs across the world. A significant proportion of them are associated with infective agents, and associations with specific genetic abnormalities are expanding. Precise classification of some of these entities has been difficult and “grey” zones between different entities are well accepted. The role of gene expression and microRNA expression in defining disease biology has generated wide interest. Apart from tumour-related attributes, the microenvironment in these diseases play a major role in disease biology. Furthermore, appropriate management of these patients to achieve cure has been challenging. To achieve this in the background of different geographic and economic settings adds yet another dimension.

We are particularly interested in compiling manuscripts that address the above issues in various ABLs. Potential topics include, but are not limited to:

• Epidemiology
• Association with infective agents
• Genetic abnormalities and epigenetic alterations
• Issues related to disease classification
• Gene and microRNA expression
• Microenvironment
• Disease management
• Biomarkers of the following diseases:
  • B-lymphoblastic lymphoma
  • Mantle cell lymphoma
  • Burkitt's lymphoma
  • Diffuse large B-cell lymphoma
  • Other large B-cell lymphomas
  • Lymphomas in immune deficiency states
  • Grey zone lymphomas

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ah/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: